2024-09-30 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis Report

**1. Performance Comparison:**

Pfizer Inc. (PFE) is a pharmaceutical giant, known for developing and manufacturing medicines and vaccines. 

* **Cumulative Return:** PFE has a cumulative return of **-11.79%**, significantly lagging behind the S&P 500 (VOO) with a return of **133.28%**. 
* **Divergence:** The relative divergence is currently at **-145.07**, meaning PFE is underperforming the S&P 500 by a large margin, ranking at the lowest 84th percentile based on historical data.

**2. Recent Price Movement:**

* **Closing Price:** $29.18
* **5-Day Moving Average:** $29.15
* **20-Day Moving Average:** $29.22
* **60-Day Moving Average:** $29.24

The price is currently below all moving averages, suggesting a potential short-term downtrend.

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 46.6. This indicates that PFE is currently in a neutral territory, neither overbought nor oversold.
* **PPO (Percentage Price Oscillator):** -0.16. A negative value suggests that the price is declining relative to its moving average, further supporting the potential short-term downtrend.
* **Delta_Previous_Relative_Divergence:** -2.42. The negative value suggests a recent decline in relative performance, potentially indicating further short-term weakness.
* **Expected Return:** 0.0%. This suggests a limited expected return for the next 5 years based on current investment levels.

**4. Recent Earnings Performance and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-30 | 0.6 | 0.458 |
| 2024-05-01 | 0.82 | 0.516 |
| 2024-01-30 | 0.1 | -0.19 |
| 2023-10-31 | -0.17 | -0.32 |
| 2023-08-01 | 0.67 | 0.56 |

The most recent earnings report for the quarter ended July 30, 2024, showed an EPS of $0.6 exceeding the analyst expectation of $0.458.  This is positive news for PFE, as it indicates a potential for better-than-expected performance. However, it is important to consider the long-term trend and the impact of various factors such as patent expirations and competition in the pharmaceutical industry.

**5. News and Recent Issues:**

Recent market outlook for PFE is mixed. While some analysts remain optimistic about the company's long-term growth prospects, others are concerned about the potential impact of generic competition and a slowdown in revenue growth.  Pfizer is currently facing intense competition from generic manufacturers for its key drugs, particularly for its COVID-19 vaccine and treatment, which could put pressure on pricing and profitability.  

**6. Overall Analysis:**

PFE is currently underperforming the market significantly, and its recent price action suggests a possible short-term downtrend.  Despite the recent positive earnings beat, long-term challenges remain. The company's reliance on a few blockbuster drugs with expiring patents, along with increasing competition, creates uncertainty for investors. The technical indicators are mixed, indicating a neutral sentiment for PFE.  Investors should closely monitor the company's performance in the coming quarters to evaluate the long-term prospects.  

**7. Conclusion:**

Pfizer Inc. faces a number of challenges in the coming years. While the recent earnings beat is encouraging, the company's future growth remains uncertain due to expiring patents and intensifying competition. Investors need to carefully consider the risks and potential rewards before investing in PFE.
